EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen access · CC BY-NC 4.0

Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial

Lawrence F Eichenfield iD, Rocco Serrao, Vimal H Prajapati iD, John C Browning iD, Lisa Swanson, Tracy Funk iD, Mercedes E Gonzalez iD, Adelaide A Hebert iD, Mark Lee iD, Mark Boguniewicz iD, Eric L Simpson, Melissa S Seal and 8 more

Pediatric Dermatology · 2025

DOI: 10.1111/pde.15840 ↗

At a glance

Randomisierte kontrollierte Studie in Pediatric Dermatology, 2025. Written by Lawrence F Eichenfield and 19 co-authors. Institution: University of California San Diego, La Jolla, California, USA, Rady Children's Hospital - San Diego, San Diego, California, USA. Major MEDLINE topics: Dermatitis, Atopic, Benzamides, Aminopyridines, Phosphodiesterase 4 Inhibitors. Cited 5 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Arcutis Biotherapeutics, Inc..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background/Objectives Efficacy and safety of roflumilast cream 0.15% were demonstrated in patients aged ≥ 6 years with atopic dermatitis (AD) in two Phase 3 trials. This Phase 3 parallel‐group, double‐blind trial (INTEGUMENT‐PED; NCT04845620) compared the efficacy and safety of roflumilast cream 0.05% and a vehicle in patients aged 2–5 years with AD.

Methods

Patients aged 2–5 years with mild‐to‐moderate AD were treated with once‐daily roflumilast cream 0.05% or vehicle for 4 weeks. The primary efficacy endpoint was Validated Investigator Global Assessment for AD (vIGA‐AD) Success (0 [Clear] or 1 [Almost Clear] plus ≥ 2‐grade improvement from baseline) at Week 4. Other endpoints included ≥ 75% improvement in Eczema Area and Severity Index (EASI‐75) and Worst Itch‐Numeric Rating Score (WI‐NRS) Success (≥ 4‐point improvement in patients with baseline ≥ 4). Safety and tolerability were also assessed.

Results

Among 437 and 215 patients treated with roflumilast and vehicle, respectively, significantly greater proportions of the roflumilast group achieved Week‐4 vIGA‐AD Success (25.4% vs. 10.7%; p < 0.0001), EASI‐75 (39.4% vs. 20.6%; p < 0.0001), and WI‐NRS Success (35.3% vs. 18.0%; nominal p = 0.0002). Improvement in pruritus was observed within 24 h after the first application (nominal p = 0.0014). Treatment‐emergent adverse event (TEAE) rates were low in both groups, and 98.9% were mild or moderate. At all timepoints, stinging/burning that caused definite discomfort was reported by ≤ 0.7% of caregivers of patients in the roflumilast group.

Conclusions

In this Phase 3 trial, once‐daily roflumilast cream 0.05% improved AD signs/symptoms in patients aged 2–5 years, with early pruritus improvement, low AE rates, and local tolerability comparable with vehicle. Trial Registration: ClinicalTrials.gov : NCT04845620

Subjects

MeSH terms (MEDLINE)

Dermatitis, AtopicBenzamidesAminopyridinesPhosphodiesterase 4 InhibitorsHumansMaleChild, PreschoolFemaleDouble-Blind MethodCyclopropanesTreatment OutcomeSeverity of Illness IndexDrug Administration ScheduleSkin Cream

Author keywords

atopic dermatitiseczemanonsteroidal topicalpediatricspruritusroflumilast

Substances

RoflumilastBenzamidesAminopyridinesCyclopropanesPhosphodiesterase 4 Inhibitors

Authors and institutions

  • University of California San Diego, La Jolla, California, USA, Rady Children's Hospital - San Diego, San Diego, California, USA.
  • DOCS Dermatology, Mason, Ohio, USA.
  • Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Pe…
  • Texas Dermatology and Laser Specialists, San Antonio, Texas, USA.
  • Ada West Dermatology, Meridian, Idaho, USA.
  • Oregon Health and Science University, Portland, Oregon, USA.

ORCID profiles: Lawrence F Eichenfield, Vimal H Prajapati, John C Browning, Tracy Funk, Mercedes E Gonzalez, Adelaide A Hebert, Mark Lee, Mark Boguniewicz, Erin Almaraz

Funding

  • Arcutis Biotherapeutics, Inc.

Cite

APA

Eichenfield, L. F., Serrao, R., Prajapati, V. H., Browning, J. C., Swanson, L., Funk, T., Gonzalez, M. E., Hebert, A. A., Lee, M., Boguniewicz, M., Simpson, E. L., Seal, M. S., Krupa, D., Hanna, D., Snyder, S., Burnett, P., Chu, D. H., Almaraz, E., Higham, R. C., & Berk, D. R. (2025). Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial. Pediatric Dermatology. https://doi.org/10.1111/pde.15840

Vancouver

Eichenfield LF, Serrao R, Prajapati VH, Browning JC, Swanson L, Funk T, et al. Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial. Pediatric Dermatology. 2025. doi:10.1111/pde.15840

BibTeX
@article{Eichenfield2025,
  author = {Eichenfield, Lawrence F and Serrao, Rocco and Prajapati, Vimal H and Browning, John C and Swanson, Lisa and Funk, Tracy and Gonzalez, Mercedes E and Hebert, Adelaide A and Lee, Mark and Boguniewicz, Mark and Simpson, Eric L and Seal, Melissa S and Krupa, David and Hanna, Diane and Snyder, Scott and Burnett, Patrick and Chu, David H and Almaraz, Erin and Higham, Robert C and Berk, David R},
  title = {Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial},
  journal = {Pediatric Dermatology},
  year = {2025},
  doi = {10.1111/pde.15840}
}
Start for free →